KDR and hepatocellular carcinoma: The CARES-310 study (NCT03764293), which recently disclosed data, demonstrated that apatinib, a selective VEGFR2 small molecule inhibitor, in combination with the PD-1 monoclonal antibody camrelizumab had a superior benefit over sorafenib, and therefore this combination is currently approved by the National Medical Products Administration (NMPA) as first-line therapy for unresectable or metastatic HCC.33 Moreover, apatinib monotherapy, which prolonged survival and response rates in advanced HCC compared to placebo as a second-line therapy, has now been approved by the NMPA.